Retatrutide 20mg

Retatrutide 20mg Research Peptide

Retatrutide 20mg is a synthetic peptide research material intended exclusively for laboratory, analytical, and scientific research applications.

Retatrutide, also identified in research literature as LY3437943, is an investigational GIP, GLP-1, and glucagon receptor agonist. These three receptor systems are involved in metabolic and cellular signaling, making the compound of interest for controlled experimental research. Lilly continues to classify retatrutide as investigational and, as of September 2026, it has not been approved by the FDA or any other regulatory agency.

Laboratory research involving retatrutide may examine:

• GIP receptor signaling
• GLP-1 receptor signaling
• Glucagon receptor signaling
• Multi-receptor interaction studies
• Metabolic signaling pathways
• Cellular bioenergetics
• Receptor activation and downstream signaling
• Peptide characterization
• Structure–activity relationships
• Analytical method development
• In-vitro metabolic research models

Research findings involving retatrutide remain part of an ongoing investigational program and should not be interpreted as establishing safety, efficacy, dosage, or therapeutic benefit for products sold outside authorized clinical research.

Product Information

• Product: Retatrutide
• Strength: 20mg
• Research Identifier: LY3437943
• Classification: Synthetic research peptide
• Receptor Targets: GIP / GLP-1 / Glucagon
• Research Area: Metabolic Research
• Intended Setting: Laboratory, analytical, and scientific research
• Supplier: Peptides R US

Regulatory / Research Use Notice

This product is offered solely for legitimate laboratory, analytical, and scientific research purposes.

It is not intended for human or veterinary consumption or administration and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

No dosage, injection, reconstitution-for-human-use, weight-management, therapeutic, or clinical-use instructions are provided or implied.

FDA currently states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under U.S. federal law.

FDA has also issued warning letters to sellers offering retatrutide online where the overall marketing indicated human drug use, including situations involving research-oriented terminology.